NeoGenomics launches PanTracer Tissue and HRD-enhanced profiling to accelerate ovarian cancer treatment decisions

NeoGenomics, Inc. (NASDAQ: NEO) has expanded its precision oncology offerings with the commercial rollout of PanTracer™ Tissue and PanTracer™ Tissue + HRD, two advanced diagnostic solutions unveiled during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These next-generation solid tumor profiling assays are designed to provide oncologists with faster, more comprehensive genomic insights, enabling more personalized cancer care—especially for ovarian cancer patients.

The Florida-headquartered cancer diagnostics leader announced that PanTracer Tissue can now analyze over 500 cancer-associated genes, aligning with leading clinical guidelines to support therapy decisions and clinical trial enrollment. The HRD-enhanced version incorporates homologous recombination deficiency testing, including BRCA mutation and genomic instability scores, which are crucial biomarkers for tailoring treatment strategies using PARP inhibitors and other DNA repair pathway-targeting agents.

With turnaround times as fast as eight days and broad compatibility across specimen types, NeoGenomics’ latest tools aim to significantly shorten the decision-making window for oncologists—offering high clinical utility, particularly in high-burden and aggressive tumors like ovarian cancer.

Why is NeoGenomics’ new PanTracer HRD test considered a breakthrough for ovarian cancer therapy selection?

Ovarian cancer presents a unique clinical challenge due to its late-stage diagnosis and variable response to standard therapies. In this landscape, HRD status, BRCA mutations, and genomic instability have emerged as critical predictive indicators for response to targeted drugs such as PARP inhibitors.

NeoGenomics’ newly launched PanTracer Tissue + HRD test integrates these elements into a single, comprehensive assay. It evaluates BRCA1/2 mutation status alongside a genomic instability score to guide therapeutic decisions. Unlike earlier two-step diagnostic processes that required multiple specimen submissions, this single-sample approach simplifies workflows while boosting diagnostic yield.

Incorporating HRD assessment directly into its tissue-based platform gives physicians a unified, guideline-concordant diagnostic tool to evaluate ovarian tumors. This test goes beyond detecting just BRCA alterations by also uncovering broader deficiencies in the homologous recombination pathway—a key driver of DNA repair failure in cancer.

According to institutional observers, this comprehensive profiling framework supports not just regulatory-aligned treatment planning, but also accelerates patient stratification for clinical trials, which often hinge on biomarker-specific eligibility. The rapid result delivery, with minimal specimen input, enhances its viability across both community practices and academic cancer centers.

How does PanTracer Tissue build on NeoGenomics’ prior comprehensive genomic profiling capabilities?

PanTracer Tissue is the evolution of NeoGenomics’ previously known NeoComprehensive® Solid Tumor assay, which offered pan-cancer gene coverage but lacked integrated HRD functionality. The updated platform expands the biomarker panel to over 500 genes and streamlines the analytical workflow for solid tumors.

This latest iteration maintains the foundation of next-generation sequencing (NGS) while upgrading variant detection, fusion identification, and tumor mutation burden evaluation. PanTracer also supports reflex testing protocols, allowing additional biomarker exploration without re-biopsy—a common bottleneck in oncology diagnostics.

By covering the full scope of clinically actionable genomic alterations across tumor types, including lung, colorectal, breast, and now ovarian cancers, PanTracer aims to close the gap between diagnosis and treatment initiation. Furthermore, the assay follows the latest National Comprehensive Cancer Network (NCCN) and ESMO clinical guidelines, ensuring that reported biomarkers match current therapy recommendations and emerging trial frameworks.

Clinical genomics experts emphasize that faster, richer, and more clinically relevant diagnostics are becoming essential to meet the expectations of modern oncology. PanTracer’s 8-day turnaround time and minimal tissue requirement signal NeoGenomics’ ability to cater to both time-sensitive and limited-sample oncology cases—especially relevant in metastatic settings.

What do analysts believe about the commercial impact and market positioning of NeoGenomics’ expanded test portfolio?

Institutional investors and oncology stakeholders view the PanTracer launch as a strategically timed expansion that aligns with increasing biomarker-driven oncology paradigms. With competitors like Foundation Medicine and Caris Life Sciences also intensifying their HRD testing efforts, NeoGenomics’ dual offering places it firmly within the high-growth precision oncology diagnostic segment.

Analysts note that BRCA mutation testing and HRD profiling are now reimbursable under several payer frameworks in the U.S., boosting commercial uptake potential. Moreover, expanding test panels with HRD inclusion may drive higher average selling prices (ASPs) per test, improving revenue per patient across NeoGenomics’ broad oncology network.

The launch also deepens NeoGenomics’ value proposition with biopharmaceutical clients, many of whom are seeking companion diagnostics and trial screening solutions. PanTracer’s unified design helps streamline biomarker selection for drug development programs, particularly in gynecologic cancers where biomarker stratification is increasingly required by regulators.

While NeoGenomics has faced growth challenges in previous quarters, including revenue fluctuations and cost optimization cycles, the PanTracer expansion is seen by market observers as a return to innovation leadership, reinforcing its long-term growth thesis in molecular pathology.

How does PanTracer Tissue + HRD affect physician workflows and treatment pathways across oncology networks?

The integration of HRD profiling into a single, all-in-one assay represents a workflow transformation for clinicians, especially in multidisciplinary cancer centers. Traditionally, oncologists needed to order multiple tests to confirm BRCA status and genomic instability, leading to delays, increased costs, and repeat biopsies.

NeoGenomics’ unified platform eliminates those barriers. By covering guideline-recommended genes and HRD in one test, PanTracer supports more confident, timely decisions around initiating platinum-based chemotherapy or adding PARP inhibitors.

Clinical leaders at large hospital systems have also emphasized the efficiency and scalability of NeoGenomics’ approach. Since PanTracer requires minimal tumor tissue, it’s usable even with fine-needle biopsies or archived formalin-fixed paraffin-embedded (FFPE) blocks, expanding access in resource-constrained settings.

Further, the new test interfaces seamlessly with existing electronic medical record (EMR) systems, improving report readability, interpretation speed, and integration with tumor board decision-making. This plug-and-play architecture is increasingly a deciding factor for hospital procurement teams choosing between competing genomic testing providers.

What does NeoGenomics’ product expansion signal about its long-term precision oncology roadmap?

The announcement of PanTracer Tissue and PanTracer Tissue + HRD marks another step in NeoGenomics’ strategic shift from legacy pathology services toward molecular-first, guideline-aligned testing platforms. Having previously expanded its liquid biopsy solutions and lab network footprint in both the U.S. and UK, the company is now anchoring growth on innovation in high-value diagnostics.

With this launch at ASCO 2025, NeoGenomics is doubling down on tumor-agnostic profiling technologies that cater to both clinicians and drug developers. Its recent internal investment in NGS infrastructure, bioinformatics pipelines, and regulatory compliance also supports scalability across disease states and payer ecosystems.

Future directions may include extending HRD profiling to additional tumor types like prostate, pancreatic, and triple-negative breast cancers—each of which has shown responsiveness to DNA-damage-targeting therapies. Analysts expect further integration of AI-based variant interpretation and decentralized testing models, allowing faster deployment in global oncology markets.

From an investor standpoint, the success of PanTracer Tissue + HRD will be measured not just by test volumes, but also by its role in clinical decision-making influence, therapy enablement, and biopharma partnerships—all key drivers of revenue diversification and shareholder confidence.

What’s next for NeoGenomics and its PanTracer portfolio following ASCO 2025?

Following the official rollout at the 2025 ASCO Annual Meeting, NeoGenomics plans to scale adoption across hospital systems, independent oncology clinics, and international laboratory partners. With both CAP-accredited and CLIA-certified facilities in the United States and Cambridge, UK, the cancer diagnostics developer is equipped to handle multi-region specimen processing and reporting.

Looking forward, additional features such as liquid biopsy compatibility, real-time tracking, and automated clinical trial matching algorithms may be layered onto the PanTracer portfolio. These enhancements would further differentiate NeoGenomics in a crowded molecular diagnostics space.

Experts anticipate that broader payer recognition of HRD as a routine biomarker will also spur greater test adoption, especially as more treatment regimens become biomarker-conditional. Institutional sentiment remains positive, with observers calling PanTracer “a strategically timed move that reflects NeoGenomics’ transition from a volume-based to a value-based diagnostic leader.”

As next-generation sequencing becomes central to value-based oncology, NeoGenomics appears poised to play a growing role in translating complex genomic data into real-world therapeutic outcomes—just as precision medicine enters its next chapter.